Modified anthrax toxin protective antigen

US10835593B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Shi-Hui Liu · Bethesda, US
• Stephen H. Leppla · Bethesda, US
• Thomas Bugge · Bethesda, US
• Alexander N. Wein · Decatur, US
• Diane E. Peters · Grafton, US
• Jie Liu · Houston, US
• Kuang-Hua Chen · Gaithersburg, US

Key dates

• Filing date: Aug 25, 2016
• Grant date: Nov 17, 2020
• Expiry date: Aug 25, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/55522
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a Bacillus anthracis protective antigen (PA) comprising a PA amino acid sequence, wherein one or more of amino acid residues I207, I210, E654, I656, R659, M662, Y681, and L687, as defined by reference to SEQ ID NO: 1, are, independently, substituted, with the proviso that amino acid residue I207 is not substituted with alanine and amino acid residue I210 is not substituted with alanine. Related compositions, nucleic acids, recombinant expression vectors, host cells, populations of cells, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.